Figure 2: Probability of overall survival based on baseline presence or absence of hepatic metastases, performance status, treatment agents, sex, and laboratory values.

Kaplan-Meier survival curves for subjects stratified based on A) baseline presence of hepatic (vs. extrahepatic-only) metastases, B) baseline ECOG performance score, C) use of anti-CTLA4 therapy, D) use of anti-PD-1 therapy, E) sex, F) LDH, and G) ALP. Numbers of subjects and median overall survival with 95% CI are shown for each subgroup. Statistical significance tested using two-sided log-rank test.